Equities

Windtree Therapeutics Inc

WINT:NAQ

Windtree Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.57
  • Today's Change-0.069 / -1.90%
  • Shares traded7.62k
  • 1 Year change-84.50%
  • Beta0.6198
Data delayed at least 15 minutes, as of May 31 2024 20:50 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Windtree Therapeutics, Inc. is a biotechnology company. The Company is focused on advancing early and late-stage therapies for critical conditions and diseases. The Company’s portfolio of product candidates includes istaroxime, a Phase II candidate with SERCA2a activating properties for acute heart failure and associated cardiogenic shock, pre-clinical SERCA2a activators for heart failure and VAR-101 and VAR-102, pre-clinical precision atypical protein kinase C iota (aPKCi) inhibitors that are being developed for potential in rare and broad oncology applications. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum, enhancing calcium reuptake from the cytoplasm. It also has a licensing business model with partnership out-licenses in place.

  • Revenue in USD (TTM)0.00
  • Net income in USD-5.96m
  • Incorporated1992
  • Employees15.00
  • Location
    Windtree Therapeutics Inc2600 Kelly Rd Ste 100WARRINGTON 18976-3652United StatesUSA
  • Phone+1 (215) 488-9300
  • Fax+1 (215) 488-9301
  • Websitehttps://windtreetx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hi-Great Group Holding Co109.49k-121.76k1.78m--------16.26-0.0012-0.00120.0011-0.00110.82240.8406-----91.46------46.50---111.21--0.0144-52.41-----47.32---3,789.70------
SYBLEU Inc11.70k-307.88k1.84m--------157.17-0.0293-0.02930.0011-0.03670.0641-------168.63-----------2,631.45-----8.484.96--0.00--26.51------
SOHM Inc-100.00bn-100.00bn1.84m--------------------------------------------------------------
CanaQuest Medical Corp0.00-808.07k1.92m-----------0.0514-0.05140.00-0.0370.00-------1,084.38--------------------------57.42------
Panbela Therapeutics Inc0.00-27.26m1.94m7.00---------20.38-20.380.00-0.65630.00----0.00-201.94-215.89-809.38-476.38-----------161.794.16------27.68------
Twinlab Consolidated Holdings Inc12.65m-9.55m1.94m17.00------0.1537-0.0369-0.05020.0488-0.54471.011.497.30743,941.20-76.13-60.53----34.5921.36-75.51-37.720.0094-0.0108-----20.87-28.58-20.28------
VG Life Sciences Inc0.00-4.30m2.11m7.00---------0.0721-0.07210.00-0.04910.00-------384.41-294.08-----------587,591.90---1.70--------16.58------
America Great Health219.13k-859.20k2.11m7.00------9.64-0.00004-0.000040.00001-0.00020.67460.072118.1631,304.29-265.62-543.96----95.92-247.36-393.74-1,193.550.035-1.37----95.23--84.35------
Windtree Therapeutics Inc0.00-5.96m2.11m15.000.19270.1181----18.5318.530.0030.230.00----0.00-18.26-44.51-20.72-48.38-------94,533.34----0.00------48.25------
Link Reservations Inc0.00-480.90k2.11m0.00---------46.51-46.510.00-13.990.00-------246.84-----------------2.43---------22.69------
CYANOTECH CORP22.49m-4.62m2.12m86.00--0.1518--0.0941-0.7265-0.72653.532.010.78891.5310.73261,546.50-16.19-2.32-21.07-2.9629.5935.88-20.52-2.330.3702-5.930.3299---35.56-7.44-259.70--1.22--
American Green Inc-100.00bn-100.00bn2.14m6.00------------------------------------------------------------
Salarius Pharmaceuticals Inc0.00-8.92m2.21m2.00--0.5476-----2.71-2.710.000.84590.00----0.00-119.38-69.27-193.68-79.89-------675.70----0.031------60.32------
Galmed Pharmaceuticals Ltd0.00-6.91m2.22m3.00--0.1345-----3.68-3.680.002.750.00----0.00-41.65-45.06-50.55-50.79------------0.00------61.31------
Data as of May 31 2024. Currency figures normalised to Windtree Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

0.72%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 20242.31k0.45%
Geode Capital Management LLCas of 31 Mar 2024777.000.15%
Citadel Securities LLCas of 31 Mar 2024592.000.12%
Wells Fargo Bank, NA (Private Banking)as of 31 Mar 20242.000.00%
UBS Financial Services, Inc.as of 31 Mar 20241.000.00%
Alyeska Investment Group LPas of 31 Mar 20240.000.00%
Virtu Americas LLCas of 31 Mar 20240.000.00%
UBS Securities LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.